Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation.

Voss SD, Hank JA, Nobis CA, Fisch P, Sosman JA, Sondel PM
Cancer Immunol Immunother. 1989 29 (4): 261-9

PMID: 2787694 · DOI:10.1007/BF00199214

MeSH Terms (12)

Carcinoma, Renal Cell Cytotoxicity, Immunologic Humans Immunity, Cellular Immunotherapy Interleukin-2 In Vitro Techniques Leukocyte Count Lymphocyte Activation Lymphocytes Melanoma Receptors, Interleukin-2

Connections (1)

This publication is referenced by other Labnodes entities: